ATE382337T1 - Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer - Google Patents

Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer

Info

Publication number
ATE382337T1
ATE382337T1 AT06008539T AT06008539T ATE382337T1 AT E382337 T1 ATE382337 T1 AT E382337T1 AT 06008539 T AT06008539 T AT 06008539T AT 06008539 T AT06008539 T AT 06008539T AT E382337 T1 ATE382337 T1 AT E382337T1
Authority
AT
Austria
Prior art keywords
molecular weight
less
release
fraction content
base material
Prior art date
Application number
AT06008539T
Other languages
English (en)
Inventor
Tatsuaki Miyaji
Makoto Sato
Tamaki Murayama
Yohei Hoashi
Hisae Saito
Takao Okada
Yukari Imamura
Yoshimichi Fujiyama
Original Assignee
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipro Corp filed Critical Nipro Corp
Application granted granted Critical
Publication of ATE382337T1 publication Critical patent/ATE382337T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06008539T 2005-04-28 2006-04-25 Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer ATE382337T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005131893 2005-04-28

Publications (1)

Publication Number Publication Date
ATE382337T1 true ATE382337T1 (de) 2008-01-15

Family

ID=36952555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06008539T ATE382337T1 (de) 2005-04-28 2006-04-25 Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer

Country Status (4)

Country Link
US (1) US7342048B2 (de)
EP (1) EP1716847B1 (de)
AT (1) ATE382337T1 (de)
DE (1) DE602006000381T2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) * 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
AU2007207618B2 (en) 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
EP2689022B1 (de) 2011-03-23 2018-04-25 The United States of America, as represented by The Secretary, Department of Health and Human Services Zusammensetzungen und verfahren zur verstärkung der pluripotenz von stammzellen
JP6129155B2 (ja) 2011-04-12 2017-05-17 ライジェル ファーマシューティカルズ， インコーポレイテッド 同種移植片拒絶反応を抑制する方法
CA2835825C (en) 2011-05-13 2021-03-23 Minoru S.H. Ko Use of zscan4 and zscan4-dependent genes for direct reprogramming of somatic cells
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
RU2735141C2 (ru) 2013-03-15 2020-10-28 Иликсиэджен Терапьютикс, Инк. Способы применения zscan4 для омоложения человеческих клеток
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
CA2941357A1 (en) 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
CA3112627A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
WO2020069018A1 (en) 2018-09-26 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
EP3860635A4 (de) 2018-10-04 2022-07-06 Rutgers, The State University of New Jersey Verfahren zur verminderung der typ-2-zytokinvermittelten entzündung mit neuromedin-peptiden
MX2021008832A (es) 2019-02-08 2021-09-08 Krystal Biotech Inc Composiciones y metodos para la administracion de polipeptidos cftr.
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
CA3149164A1 (en) 2019-09-03 2021-03-11 Suma Krishnan Compositions and methods for the treatment of congenital ichthyoses
CN110882222B (zh) * 2019-12-05 2021-12-03 北京博恩特药业有限公司 颗粒组合物及制备方法和应用
US20210189427A1 (en) 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
CN111658620B (zh) * 2020-04-30 2022-04-19 天津医科大学口腔医院 一种透明质酸-帕瑞昔布plga微球及其制备方法和应用
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
AU2022246917A1 (en) 2021-04-02 2023-10-12 Krystal Biotech, Inc. Viral vectors for cancer therapy
AU2024229184A1 (en) 2023-03-02 2025-08-28 Krystal Biotech, Inc. Interleukin-2 and interleukin-12 for cancer therapy
CN121569045A (zh) 2023-04-13 2026-02-24 克里斯托生物技术股份有限公司 治疗涉及眼睛的病症的方法和组合物
WO2026094007A1 (en) 2024-11-01 2026-05-07 Krystal Biotech, Inc. Compositions and methods for the treatment of atpase disorders or diseases of the skin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328204A (en) 1977-03-02 1982-05-04 Ethicon, Inc. Absorbable polymer-drug compounds and method for making same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60181029A (ja) 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
JP3168263B2 (ja) 1984-07-06 2001-05-21 和光純薬工業株式会社 新規重合体及びこれを用いた医薬
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
EP0452111B1 (de) * 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
JP3254449B2 (ja) 1990-04-13 2002-02-04 武田薬品工業株式会社 生体内分解型高分子重合物
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5614390A (en) 1996-06-14 1997-03-25 Becton, Dickinson And Company Species-specific detection of Mycobacterium kansasii
ES2221019T3 (es) * 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
CA2316273A1 (en) 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Sustained-release composition, method of its production and use thereof
US7019106B2 (en) 2000-08-07 2006-03-28 Wako Pure Chemical Industries, Ltd. Lactic acid polymer and process for producing the same
JP2004155792A (ja) 2001-06-29 2004-06-03 Takeda Chem Ind Ltd 徐放性組成物およびその製造法
JP3902518B2 (ja) 2001-06-29 2007-04-11 武田薬品工業株式会社 徐放性組成物用乳酸−グリコール酸重合体の製造法
JP5188670B2 (ja) 2001-06-29 2013-04-24 武田薬品工業株式会社 徐放性組成物およびその製造法
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same

Also Published As

Publication number Publication date
US7342048B2 (en) 2008-03-11
DE602006000381T2 (de) 2008-12-18
DE602006000381D1 (de) 2008-02-14
EP1716847A1 (de) 2006-11-02
US20060246139A1 (en) 2006-11-02
EP1716847B1 (de) 2008-01-02

Similar Documents

Publication Publication Date Title
DE602006000381D1 (de) Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
BRPI0812064B8 (pt) formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica
WO2009132265A3 (en) Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
NO20071853L (no) Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose.
MX2007000009A (es) Forma farmaceutica oral, protegida frente al abuso.
WO2006017852A3 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
WO2009129300A3 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
CY1109606T1 (el) Βιοδιασπωμενο υμενιο για την απελευθερωση φαρμακου στον οφθαλμο
CY1117889T1 (el) Πολυμερες γαλακτικου οξεος και διεργασια για την παραγωγη αυτου
CO5570662A2 (es) Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
WO2010138544A3 (en) Oral care formulations that enhance amount of soluble zinc
WO2004026256A3 (en) Sustained-release opioid formulations and methods of use
MX336861B (es) Formulacion de farmaco resistente al abuso.
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
EA200900246A1 (ru) Подкожные имплантаты, высвобождающие активный компонент в течение продолжительного периода времени
WO2006099514A3 (en) Drug delivery compositions and related methods
TN2009000476A1 (en) Slow release pharmaceutical composition made of microparticles
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
BR0212052A (pt) Preparação de composição farmacêutica de liberação prolongada
DE3872739D1 (de) Arzneimittel mit langsamer freisetzung.
PE20030066A1 (es) Composicion de liberacion controlada y metodo para producirla
BRPI0620185B8 (pt) formulação farmacêutica, comprimidos, e, processo para a preparação de uma formulação farmacêutica
BR0214159A (pt) Sistema farmacêutico radiopaco de liberação prolongada
GB0209749D0 (en) Compositions and methods

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1716847

Country of ref document: EP